NTRK2 and neoplasm: As to whether the priming effect of tumor-derived kynurenine on AhR activation in platelets contributes to variations in the platelet NAS/melatonin ratio, in turn driving an increase in TrkB-T levels, activation and ligands, will be important to determine.